After the US Food and Drug Administration declined to approve Coptic Therapeutics's drugs to treat rare hormone disorders, the company's stock price fell 34.5% in pre-market trading.

Zhitongcaijing · 12/31/2025 13:33
After the US Food and Drug Administration declined to approve Coptic Therapeutics's drugs to treat rare hormone disorders, the company's stock price fell 34.5% in pre-market trading.